Related Experiment Videos
Rates and dates of divergence between AIDS virus nucleotide sequences
W H Li1, M Tanimura, P M Sharp
1Center for Demographic and Population Genetics, University of Texas, Houston 77225.
Molecular Biology and Evolution
|July 1, 1988
Summary
Human immunodeficiency virus (HIV) exhibits rapid nucleotide substitution rates, significantly higher than DNA viruses. This rapid evolution, particularly in the envelope gene, impacts viral antigenicity and disease spread.
Area of Science:
- Virology
- Molecular Evolution
- Epidemiology
Background:
- The human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome (AIDS), a global pandemic.
- Understanding HIV's genetic mutation rate and spread patterns is crucial for developing effective treatments and vaccines.
Purpose of the Study:
- To develop a new model for estimating nucleotide substitution rates across the HIV genome.
- To analyze the evolutionary dynamics and historical spread of HIV.
Main Methods:
- A novel computational model was employed to estimate substitution rates in different HIV genomic regions.
- Nucleotide sequence data from HIV isolates were analyzed to infer evolutionary relationships.
Main Results:
- Nonsynonymous substitution rates varied significantly, with hypervariable envelope regions showing the highest rates (~14 x 10^-3/site/year) and capsid/reverse transcriptase regions the lowest (~1.7 x 10^-3/site/year).
- The average synonymous rate was ~10 x 10^-3/site/year, orders of magnitude higher than DNA genomes.
- Analysis suggested HIV existed in Central Africa before 1960 and spread to North America by the mid-1970s, with evidence of recombination between strains.
Conclusions:
- HIV's high mutation rate, especially in the envelope gene, drives rapid changes in viral antigenicity.
- The findings support the hypothesis that HIV originated in Central Africa and spread globally, with specific transmission routes inferred.
- The study provides critical insights into HIV evolution, aiding in the development of therapeutic and vaccine strategies.